Business Context and Reporting Period
This Form 8-K is a current report filed by Mast Therapeutics, Inc. (not Savara Inc.) on November 5, 2015. The filing reports the election of a new director to the Board of Directors effective immediately.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a corporate governance report rather than a financial results filing.
Material Changes
The primary material change is the appointment of Peter Greenleaf as an independent director. No financial or operational changes are reported in this document.
Compensation and Governance Details
- Director Election: Peter Greenleaf was elected to the Board on November 5, 2015, and is classified as an independent director.
- Cash Compensation: Mr. Greenleaf will receive an annual cash retainer of $35,000, payable in quarterly installments, pro-rated for the fourth quarter of 2015.
- Equity Awards: The Board granted two stock options under the 2015 Omnibus Incentive Plan:
- An "inducement option" to purchase up to 64,791 shares of common stock.
- A second option to purchase up to 37,794 shares of common stock.
- Indemnification: An Indemnification Agreement was executed, providing for the advancement of litigation expenses to the fullest extent permitted by law.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the 102,585 new option grants.
- Review the definitive proxy statement filed on April 29, 2015, for the full terms of the non-employee director compensation policy.
- Confirm the vesting schedule and exercise price of the granted options, which are not detailed in this specific 8-K.